Objective: To compare the clinical efficacy of two different dosing regimens of vaginal misoprostol for labour induction.
Material And Methods: This is an open label randomised controlled trial of 100 eligible women with obstetrical or medical indications for labour induction at a secondary level care hospital on the west coast of India. Women were randomised to receive either a single 50 μg dose or multiple 25 μg doses (maximum of three doses) of misoprostol in the posterior vaginal fornix. The main outcome measure was induction to vaginal delivery interval.
Results: Mean induction delivery interval was 18.58±13.73 and 14.42±13.2 hours (P=0.73) in the 50 μg and 25 μg misoprostol group respectively. Delivery rate within 24 hours were 60% (30/50), in 50 μg group and 68% (34/50) in 25 μg group (P=0.53). The rates of caesarean section and operative vaginal delivery were similar in both groups. There was no significant difference in maternal side effects and neonatal outcome among regimens.
Conclusion: There was no statistically significant difference between the two regimens in terms of clinical efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939169 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Deep Serratus Anterior Plane Block for Multimodal Analgesia in Minimally Invasive Mitral Valve Surgery Performed via Right Anterior Mini-Thoracotomy.
J Cardiothorac Vasc Anesth
December 2024
Department of Medical Science, Surgery and Neurosciences, Cardiothoracic and Vascular Anesthesia and Intensive Care Unit, University Hospital of Siena, Siena, Italy. Electronic address:
Objective: This study investigated if the serratus anterior plane block (SAPB) within a multimodal analgesia scheme would reduce acute post-operative pain and intravenous opioid consumption in patients admitted to the intensive care unit after isolated minimally invasive mitral valve surgery.
Design: Retrospective study.
Setting: Patients were admitted to the intensive care unit (ICU) of the University Hospital of Siena (Italy).
Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
Cancer Commun (Lond)
January 2025
Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study.
World J Diabetes
January 2025
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Background: There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin deglu-dec/aspart (IDegAsp) therapy, with insufficient data from the Chinese popu-lation.
Aim: To demonstrate the efficacy, safety, and treatment satisfaction associated with the transition to IDegAsp in type 2 diabetes mellitus (T2DM).
Methods: In this 12-week open-label, non-randomized, single-center, pilot study, patients with T2DM receiving thrice-daily insulin or intensive insulin treatment were transitioned to twice-daily injections of insulin IDegAsp.
Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population.
NPJ Syst Biol Appl
January 2025
United Therapeutics Corporation, Silver Spring, MD, USA.
Challenges in drug development for rare diseases such as pulmonary arterial hypertension can be addressed through the use of mathematical modeling. In this study, a quantitative systems pharmacology model of pulmonary arterial hypertension pathophysiology and pharmacology was used to predict changes in pulmonary vascular resistance and six-minute walk distance in the context of oral treprostinil clinical studies. We generated a virtual population that spanned the range of clinical observations and then calibrated virtual patient-specific weights to match clinical trials.
View Article and Find Full Text PDFHorse antithymocyte globulin test doses and infusion reactions in adults with aplastic anemia: A multicenter retrospective experience.
J Oncol Pharm Pract
January 2025
Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Introduction: Horse antithymocyte globulin carries a black box warning for life-threatening anaphylactic reactions, and prescribing information recommends test doses to identify patients at highest risk of this adverse effect. The predictive value of such test doses is not well validated, and practicality of use is unclear.
Methods: This was a planned secondary analysis of a multicenter, retrospective cohort study in adults with severe aplastic anemia being managed with horse antithymocyte globulin as part of their treatment regimen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!